The blockage of the hERG K+ channels has been linked to fatal cardiac arrhythmias and before any biomolecule is elected as a drug candidate, it is mandatory by the FDA to check its hERG safety. This evidence concerns the gene KCNH2 and chronic obstructive pulmonary disease.